Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Change in Intangibles (2019)

Ligand Pharmaceuticals (LGNDZ) has disclosed Change in Intangibles for 2 consecutive years, with $812.8 million as the latest value for Q1 2019.

  • Quarterly Change in Intangibles changed N/A to $812.8 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $812.8 million through Dec 2019, changed N/A year-over-year, with the annual reading at $812.8 million for FY2019, N/A changed from the prior year.
  • Change in Intangibles hit $812.8 million in Q1 2019 for Ligand Pharmaceuticals, up from -$128000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $812.8 million in Q1 2019 to a low of $812.8 million in Q1 2019.